PolyPid Ltd. (PYPD)

IL — Healthcare Sector
Peers: CUE  ANIX  INMB  INAB  EFTR  LABP  APGN  NAVB  ANGN  ANEB  ARMP  VRPX  VACC  VRAX  BWV  REVB  HILS  KPRX  PYXS  ZURA  CYTO  ELEV 

Automate Your Wheel Strategy on PYPD

With Tiblio's Option Bot, you can configure your own wheel strategy including PYPD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol PYPD
  • Rev/Share 0.0
  • Book/Share 1.4338
  • PB 2.0575
  • Debt/Equity 1.2516
  • CurrentRatio 1.3069
  • ROIC -1.3865

 

  • MktCap 30063155.0
  • FreeCF/Share 0.0
  • PFCF 0.0
  • PE -0.5447
  • Debt/Assets 0.3813
  • DivYield 0
  • ROE -6.2453

 

  • Rating C-
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Resumed PYPD H.C. Wainwright -- Buy -- $11 June 2, 2025
Initiation PYPD Rodman & Renshaw -- Buy -- $13 Jan. 28, 2025

News

PESG Research Report: Revolutionary Surgical Infection Prevention: PolyPid's D-PLEX100 Approaches Critical Phase 3 Data Readout
PYPD
Published: May 30, 2025 by: GlobeNewsWire
Sentiment: Neutral

New report from PESG Research brand covers PolyPid*, which is tackleing the $10 billion dollar a year surgeical site infections cost with its innovative PLEX technology New report from PESG Research brand covers PolyPid*, which is tackleing the $10 billion dollar a year surgeical site infections cost with its innovative PLEX technology

Read More
image for news PESG Research Report: Revolutionary Surgical Infection Prevention: PolyPid's D-PLEX100 Approaches Critical Phase 3 Data Readout
PolyPid Ltd. (PYPD) Q1 2025 Earnings Call Transcript
PYPD
Published: May 14, 2025 by: Seeking Alpha
Sentiment: Neutral

PolyPid Ltd. (NASDAQ:PYPD ) Q1 2025 Earnings Call May 14, 2025 8:30 AM ET Company Participants Brian Ritchie - Investor Relations Dikla Czaczkes Akselbrad - Chief Executive Officer Jonny Missulawin - Chief Financial Officer Ori Warshavsky - Chief Operating Officer, U.S. Conference Call Participants Roy Buchanan - JMP Securities Chase Knickerbocker - Craig-Hallum Bupalan Pachaiyappan - ROTH Capital Brian Ritchie Thank you all for participating in PolyPid's First Quarter 2025 Earnings Conference Call.

Read More
image for news PolyPid Ltd. (PYPD) Q1 2025 Earnings Call Transcript
PolyPid to Participate in The Citizens Life Sciences Conference
PYPD
Published: April 22, 2025 by: GlobeNewsWire
Sentiment: Neutral

PETACH TIKVA, Israel, April 22, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that the Company's management will participate in a fireside chat at The Citizens Life Sciences Conference taking place in New York, NY, from May 7-8, 2025.

Read More
image for news PolyPid to Participate in The Citizens Life Sciences Conference
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results
PYPD
Published: February 12, 2025 by: GlobeNewsWire
Sentiment: Neutral

Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients SHIELD II Enroll ed more than 7 00 P atients to D ate; Enrollment Completion Expected in March 202 5 , with T op- L ine Results Anticipated in Second Quarter of 2025 Company Completed Private Placement of Up to $41 Million; Proceeds and Exercise of Data-Triggered Warrant s Expected to Extend Cash Runway Beyond Potential NDA Approval Conference Call S cheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, Feb. 12, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” …

Read More
image for news PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results

About PolyPid Ltd. (PYPD)

  • IPO Date 2020-06-26
  • Website https://www.polypid.com
  • Industry Biotechnology
  • CEO Ms. Dikla Czaczkes Akselbrad
  • Employees 57

PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.